Provided by Tiger Fintech (Singapore) Pte. Ltd.

Disc Medicine

61.59
+0.19000.31%
Post-market: 61.590.00000.00%16:20 EDT
Volume:325.46K
Turnover:20.26M
Market Cap:2.14B
PE:-13.59
High:63.51
Open:60.98
Low:60.19
Close:61.40
52wk High:68.73
52wk Low:30.82
Shares:34.77M
Float Shares:28.68M
Volume Ratio:1.40
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.5319
EPS(LYR):-3.9613
ROE:-26.36%
ROA:-17.95%
PB:3.49
PE(LYR):-15.55

Loading ...

Disc Medicine Inc. Unveils New Corporate Presentation on Targeting Red Blood Cell Biology and Hematologic Disorders

Reuters
·
Yesterday

Disc Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Aug 27

Director Kevin Bitterman Reports Disposal of Common Shares of Disc Medicine Inc

Reuters
·
Aug 27

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

THOMSON REUTERS
·
Aug 26

Shattuck Labs Inc - Proceeds Expected to Fund Operations Into 2029

THOMSON REUTERS
·
Aug 26

Rapid7, Residio Tech, and 4 More Stocks See Action From Activist Investors -- Barrons.com

Dow Jones
·
Aug 23

Did Widening Losses in Q2 and H1 Reshape Disc Medicine's (IRON) Path to Profitability?

Simply Wall St.
·
Aug 21

Disc Medicine Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Aug 18

Director Kevin Bitterman Reports Disposal of Common Shares of Disc Medicine Inc

Reuters
·
Aug 16

Disc Medicine (IRON) Receives a Buy from Truist Financial

TIPRANKS
·
Aug 08

H.C. Wainwright Reaffirms Their Buy Rating on Disc Medicine (IRON)

TIPRANKS
·
Aug 08

Disc Medicine Reports Q2 2025 Financial Results and Clinical Progress

TIPRANKS
·
Aug 08

Director Kevin Bitterman Reports Disposal of Common Shares in Disc Medicine Inc

Reuters
·
Aug 08

Disc Medicine: Strong Financial Position and Promising Drug Pipeline Justify Buy Rating

TIPRANKS
·
Aug 08

Disc Medicine (IRON) Q2 Loss Widens 109%

Motley Fool
·
Aug 08

Disc Medicine Shares Fall After Wider-Than-Expected Q2 Loss

MT Newswires Live
·
Aug 07

Earnings Flash (IRON) Disc Medicine Posts Q2 Net Loss $1.58 a Share, vs. FactSet Est of $1.13 Loss

MT Newswires Live
·
Aug 07

Disc Medicine Inc. Announces Initiation of Phase 2 Study for DISC-3405 in Polycythemia Vera with Initial Data Expected in 2026

Reuters
·
Aug 07

Disc Medicine Q2 EPS $(1.58) Misses $(1.13) Estimate

Benzinga
·
Aug 07

Disc Medicine reports Q2 EPS ($1.58), consensus ($1.14)

TIPRANKS
·
Aug 07